Document is current
Any future updates will be listed below
-
Authors
Pernas, Sonia https://orcid.org/0000-0002-1485-5080
Forns, Xavier https://orcid.org/0000-0002-8188-1764
Martínez-Sáez, Olga https://orcid.org/0000-0001-8686-0236
Andrade, Raúl https://orcid.org/0000-0002-1565-0757
Amador, Alberto https://orcid.org/0000-0002-4837-9051
López-Miranda, Elena https://orcid.org/0000-0002-2253-739X
Bermejo, Begoña https://orcid.org/0000-0001-7773-5994
Mateos, Beatriz https://orcid.org/0000-0003-0326-4119
Cejuela, Monica https://orcid.org/0000-0002-3894-0765
Villanueva, María José https://orcid.org/0000-0002-2886-3794
Ozores, Patricia Palacios https://orcid.org/0000-0003-0410-079X
Riveiro-Barciela, Mar https://orcid.org/0000-0001-9309-2052
Bellet, Meritxell https://orcid.org/0000-0001-8859-8307
-
Funding
Funding for this research was provided by:
Novartis Farmacéutica
Fundació Institució dels Centres de Recerca de Catalunya
- License Information
-
More Information
Article History
Received: 5 March 2026
Accepted: 9 April 2026
First Online: 10 May 2026
Declarations
:
: Sonia Pernas: consulting or advisory role—Eli Lilly; Novartis; Pfizer, Daiichi Sankyo/AstraZeneca; Reveal, MSD/Merck, Gebro Pharma, and Jiangsu Hengrui; speakers’ bureau—Novartis, Lilly, Roche, Gilead Sciences, Pfizer, Daiichi Sankyo/AstraZeneca; research funding: Roche (Inst); travel, accommodations for medical congresses—Menarini, Gilead Sciences, Novartis; AstraZeneca, Roche, Pfizer; uncompensated relationships: SOLTI (board of directors). Xavier Forns: received consulting fees from Novartis.Olga Martínez: O.M.S reports advisory/consulting fees from Reveal Genomics, Roche and AstraZeneca, lecture fees from Daiichi Sankyo, Novartis, Pfizer and Eisai and travel expenses from Gilead and Novartis. Raúl Andrade: Consultant/Advisor: Abbott, Bayer, BMS, Boehringer Ingelheim, ENYO, GSK, iQure, Inventiva, Johnson & Johnson, Kainos Medicine, Roche, Ryvu Therapeutics, Sanofi. Elena López-Miranda: Honoraria and advisor collaboration—AstraZeneca and Daiichi Sankyo. Support for attending meetings and/or travel: Gilead, Daiichi Sankyo, Novartis and Roche. Begoña Bermejo: receiving fees for medical education as consulting or advisory role with Lilly, Pfizer, Menarini, Astra Zeneca, GILEAD, Novartis, Roche. Participating in a speakers’ bureau with Roche, MSD, Daiichi, Sankyo Astra Zeneca, Novartis, Lilly, Gilead. Travel, accommodation by Pfizer, Roche and Daiichi Sankyo. Beatriz Mateos: Gilead: payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events; ABBVIE: Support for attending meetings and/or travel. Mónica Cejuela Solís: declares financial relationships with Novartis, Pfizer, and Lilly, including grants for patient care improvement programs, participation in advisory boards, speaker honoraria and company-sponsored travel and accommodation. Patricia Palacios: Presentations, conference attendance, and travel expenses: AstraZeneca, Daiichi Sankyo, GSK, Lilly, Pfizer, MSD. Advisory Boards: GSK, Novartis, Clovis. Meritxell Bellet: Advisory Board: Pfizer, Novartis, Lilly, Stemline Menarini, Daiichi Sankyo. Speakers Bureau. Pfizer, Novartis, Lilly, Stemline Menarini, Daiichi Sankyo. Travel expenses: Pfizer, Novartis, Stemline Menarini, Roche. The remaining authors declare no conflicts of interest.
: This manuscript reports an expert consensus based on a structured review of previously published studies.
: No primary research involving human participants or animals was conducted by the authors.
